Skip to main content
Premium Trial:

Request an Annual Quote

Susan Siegel, Stephen Fodor, Thane Kreiner, Richard Rava, Mitchell Kennedy, Arthur Holden, Mark Stevenson, Leonard Klevan, Leroy Hood, Josh LaBaer, CombiMatrix Molecular Diagnostics, Scienion

Premium

People in the News

Susan Siegel resigned from her position as president of Affymetrix, the company said last week.

Siegel will be "transitioning from her current role" and will represent the company as president emeritus. She will stay on as an advisor and continue to report to chairman and CEO Stephen Fodor, according to Affy.

Siegel joined Affymetrix in 1998 as senior vice president of sales and marketing. Affy named her president in 1999 and appointed her to the board two years later.

The company also said that "effective immediately," Thane Kreiner, vice president of corporate affairs, has been named senior vice president of marketing and sales. Kreiner joined Affymetrix in 1993, and has held numerous roles in the company, including heading sales and marketing and project management.

Affy also said that Richard Rava, the scientific co-founder of Affymetrix, has been appointed to head of product development at the company.

In addition, Mitchell Kennedy, who previously served as vice president of global technical support and general manager of Affy's international trading business unit, has left the company, according to Kennedy.

An Affymetrix employee confirmed that Kennedy ended his employment with the company earlier this month.


Illumina has appointed Arthur Holden as senior vice president of corporate and market development, a new position. Holden will be charged with "developing relationships and partnerships with key customers in the pharmaceutical industry, large-scale research consortia and governmental bodies including the NIH and the US Food and Drug Administration," Illumina said. He will also serve as Illumina's representative on the Personalized Medicine Coalition and also help lead content development strategies for the company's products, "particularly those being developed for molecular diagnostics and clinical applications."

Holden was most recently chairman, CEO, and principal founder of First Genetic Trust. He is chairman of the Pharmaceutical Biomedical Research Consortium and the DMD Translational Research Consortium. Holden was formerly CEO of the SNP Consortium and CEO and a director of Celsis International, an industrial biotechnology company. He has an MBA from the JL Kellogg Graduate School of Management and a BSc from Union College.


Applied Biosystems announced last week that Mark Stevenson has been appointed president of the firm's molecular biology division. He previously served as president of the firm's applied markets division. Stevenson succeeds William Murray, who has resigned due to personal reasons.

Leonard Klevan has replaced Stevenson as president of the applied markets division. Klevan joined ABI earlier this year as vice president of R&D for applied markets. Before joining ABI, he was CEO of ReliaGene Technologies. He also is a former president and CEO of MiraiBio, a subsidiary of Hitachi Software Engineering, and had managed technology acquisitions and business development at Life Technologies, which was acquired by Invitrogen in 2000.


Leroy Hood, president and co-founder of Institute for Systems Biology, and Josh LaBaer, founder and director of the Institute of Proteomics at Harvard Medical School, have joined Lumera's scientific advisory board.

 

New Product Watch

CombiMatrix Molecular Diagnostics has begun shipping its first diagnostic microarray product, a chip developed with Array Genomics that uses array comparative genomic hybridization to detect genomic copy number variations associated with constitutional chromosome imbalances as well as with imbalances associated with over 40 defined genetic diseases and syndromes, such as DiGeorge and William's syndromes, according to CMDX.

CMDX said that the product is now available in Europe, but will require US Food and Drug Administration approval before it can be sold for diagnostic applications in the US. However, the company said that it will make the arrays available domestically for research purposes. The company will also soon begin offering genetic testing services in its CLIA-approved clinical laboratory, which will include use of its array CGH chip.


Scienion last week launched its sciProclimate One climate chamber, which the company claims can provide constant temperature and humidity during the binding of capture molecules onto microarray substrates in the microarray production process.

According to Scienion, the electronically controlled chamber uses a laminar airflow to achieve the desired temperature and humidity, and can process up to 32 slides in parallel.

The chamber was developed by Ribocon, a spin-off from the Max Planck Institute for Marine Microbiology.


DNA Chip Research and Toray Industries have launched their first co-developed product, the 3D-Gene Yeast Oligo Chip 6k, according to a Toray official.

Satoko Takizawa, a research associate at Toray, told BioArray News last week that the chip contains the entire yeast genome.

Takizawa added that a plan to develop other products, including a whole human genome array is on schedule. DNA Chip Research and Toray first announced their cooperation last December (see BAN 12/7/2005).

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.